The pharmacological interest in Kutaja is real and long-standing, and its place in the classical literature on diarrhoeal disease is secure. But many of the strongest claims circulating about this herb — precise trial statistics, named mechanisms, specific classical verse numbers — do not survive checking. What follows tries to separate what the classical texts actually say, and what modern pharmacology has actually shown, from the embellishment that has accreted around Kutaja.

The Plant and Its Chemistry

Holarrhena antidysenterica — also referred to as Holarrhena pubescens, known in Sanskrit as Kutaja and by common names including Kurchi, Indrajao, and Bitter Oleander — is a deciduous tree distributed through tropical India, Sri Lanka, and Southeast Asia. The bark is the principal medicinal part; the seeds (Indrayava) are also used, and are noted for their alkaloid content.

The activity of Kutaja is attributed chiefly to its steroidal alkaloids. More than thirty have been isolated from the plant, with conessine the principal one. The bark and seeds contain:

• Conessine: the major steroidal alkaloid, with amoebicidal and antibacterial activity reported in laboratory studies, and separately investigated for antiplasmodial (antimalarial) activity.
• Kurchicine, holarrhimine, conessimine, and isoconessimine: among the further steroidal alkaloids reported, contributing to the documented antimicrobial profile.
• Tannins and other astringent principles: consistent with the bark’s traditional astringent (stambhana / sangrahi) action on the gut mucosa.

Reported conessine content of standardized bark is often cited in the region of roughly 0.5–1.2% by weight, though values vary with source, plant part, and assay. For this reason reputable extracts are characterized to a defined alkaloid content rather than sold on plant weight alone.

Classical Ayurvedic Context

Kutaja holds a recognised place in Ayurvedic gastroenterology. Charaka Samhita, Chikitsa Sthana chapter 19, is devoted to Atisara (diarrhoea), and Kutaja appears there — chiefly as its fruit — as one of several drugs woven into multi-ingredient recipes, not as the chapter’s single primary herb. In the management of raktatisara (bloody diarrhoea), the chapter gives primacy to measures such as goat’s milk and cooling diet, with Kutaja fruit featuring in hemostatic compound recipes (for example combined with rasanjana, ativisha, and dhataki with honey). It is worth being precise here: raktatisara is a classical clinical category of bloody diarrhoea that overlaps with, but is not textually identical to, laboratory-confirmed amoebic dysentery. Equating the two as the same diagnosis is an anachronism.

Kutaja is equally associated with Grahani (the chronic malabsorptive and irregular-bowel disorders addressed in Charaka Chikitsa Sthana chapter 15), where its astringent, stool-binding character is valued. Both the bark (twak) and the seeds (Indrayava) are employed across the classical pharmacopoeia.

A word on dosage attribution: classical texts express quantities in traditional units (karsha, pala, anjali) and volumes in prastha and drona, not in grams and millilitres. The exact metric figures and fixed tablet strengths commonly presented online as direct classical quotations — for instance “10 g of bark in 400 ml reduced to 100 ml,” or “500 mg tablets” — are modern practical conversions and manufacturing specifications, not verbatim verses from Ashtanga Hridaya or any other classical source.

The Clinical Evidence: Amoebic Dysentery

Laboratory work supports the traditional antidysenteric reputation: in vitro and animal studies report amoebicidal activity for Kutaja extracts and for conessine in particular, which is consistent with the herb’s classical use against bloody, dysenteric diarrhoea. The effect is attributed chiefly to conessine and related steroidal alkaloids. However, the precise molecular target in Entamoeba histolytica is not firmly established; assertions that conessine acts through a single defined mechanism clearly distinct from metronidazole remain hypotheses rather than proven findings.

It is important to be candid about the human evidence. Robust, modern, controlled clinical trials specifically in confirmed amoebiasis are limited; much of the support is preclinical or derives from small, methodologically dated reports. Kutaja may have a legitimate adjunctive role, but confirmed amoebic infection should be diagnosed and treated through conventional means, with herbal support used under supervision rather than as a replacement.

Bacterial Diarrhea: Spectrum and Mechanism

The antimicrobial interest in Kutaja extends beyond Entamoeba. In vitro studies summarised in pharmacological reviews report antibacterial activity of bark extracts and the alkaloid fraction against a range of enteric organisms, including:

• Shigella species (bacillary dysentery)
• Salmonella species
• Escherichia coli
• Staphylococcus aureus

Reported potencies vary considerably with extract type and method, so specific minimum-inhibitory-concentration figures should be read as study-dependent rather than fixed properties of the herb. Beyond direct antimicrobial action, Kutaja extracts have shown antidiarrhoeal and antimotility effects in rodent models, an effect plausibly linked to the bark’s astringent tannins and to its alkaloids reducing intestinal hypermotility and secretion. The exact anti-secretory molecular pathway, however, remains under investigation and should not be stated as settled.

Irritable Bowel Syndrome and Non-Infectious Diarrhea

This is where Kutaja’s use reaches beyond overt infection into the subtler territory of functional gut disorders. Classical Ayurveda employs Kutaja for Grahani — chronic digestive disorders marked by malabsorption, variable stool consistency, and gut hypersensitivity — which maps imperfectly but meaningfully onto diarrhoea-predominant irritable bowel syndrome (IBS-D) in modern terms. The classical basis for this use is well established.

The modern controlled-trial evidence specific to Rome-criteria IBS-D is, by contrast, limited, and readers should be wary of precise trial statistics quoted without a traceable source. The rationale for trying Kutaja in IBS-D presently rests on its long traditional use in Grahani together with its astringent and antimicrobial profile, rather than on large randomised trials. One plausible (but still hypothetical) line of reasoning is that a subset of IBS-D involves low-grade mucosal disturbance and dysbiosis rather than frank infection, for which an antimicrobial, astringent herb might help; this remains a hypothesis to be tested, not an established mechanism.

Kutaja for Inflammatory Bowel Disease: Emerging Evidence

The most recent frontier for Kutaja is inflammatory bowel disease. Classical texts describe Kutaja in Pravahika (tenesmus-associated dysentery, which can resemble ulcerative colitis clinically), frequently paired with Bilwa (Aegle marmelos) — both astringent herbs traditionally directed at the intestinal mucosa.

A small randomized, single-blind study published in Ancient Science of Life (2016) compared, in 30 patients with chronic ulcerative colitis, three arms: mesalamine alone, a monoherbal Holarrhena antidysenterica extract tablet alone, and the combination, over four weeks. The herbal-containing groups showed greater reduction in abdominal pain, diarrhoea, and stool frequency, complete (100%) clearance of stool infection versus 70% with mesalamine alone, and fewer relapses on withdrawal; the authors concluded that the monoherbal formulation, alone or with mesalamine, was more efficacious than mesalamine alone in this small sample. This is a single, small, single-blind study and should be read as preliminary and hypothesis-generating: the mechanistic rationale — anti-inflammatory steroidal alkaloids plus astringent mucosal action — is reasonable, but larger, blinded trials are needed before any firm clinical recommendation.

Standard Preparations and Dosing

The doses below reflect contemporary practitioner and pharmacopoeial practice, not verbatim classical prescriptions; classical texts leave quantity and preparation to the vaidya‘s judgement in traditional units. Treat these as starting points to be individualised under a qualified practitioner, and discontinued once stools normalise.

Drug Interactions and Safety Profile

Kutaja has a good safety record at customary doses, but its alkaloid content warrants several cautions:

• Anti-diarrhoeal medications: potentially additive with loperamide; combining is usually unnecessary and may cause constipation in susceptible people.
• Antimicrobials for gut infection: when used alongside metronidazole, tinidazole, or fluoroquinolones, base the decision on clinical need; co-use is generally well tolerated but should be supervised.
• CYP enzyme effects: conessine’s steroid-like structure raises a theoretical possibility of CYP-mediated interactions, but direct human data are scarce; exercise caution with narrow-therapeutic-index drugs.
• Pregnancy: safety in pregnancy is not established; avoid therapeutic doses.
• Constipation risk: the astringent, anti-motility action can cause constipation if continued after diarrhoea resolves. Reduce or stop once stools normalise.

For broader herb–drug safety context, our pharmacologist’s guide on Ayurvedic herb-drug interactions covers the principles relevant to gastrointestinal herbs. For how Kutaja fits the wider Ayurvedic understanding of gut dysfunction, see our post on SIBO and Grahani in Ayurveda.

Quality and Sourcing Considerations

Substitution and adulteration are recognised problems in the Kutaja trade, most often involving related species — Wrightia tinctoria in particular is a common substitute, and seed material is especially prone to mix-ups. Because lower-grade material can be botanically incorrect, insist on authenticated raw material. When sourcing Kutaja:

• Request a certificate of analysis confirming Holarrhena antidysenterica (Holarrhena pubescens) identity and a stated alkaloid (conessine) content for therapeutic preparations.
• Use established GMP-certified Ayurvedic pharmacies.
• Products from manufacturers such as Baidyanath, Kottakkal Arya Vaidya Sala, or Dhootapapeshwar tend to maintain consistent standards.

In the classical tradition Kutaja is counted among the foremost astringent (sangrahi) drugs for diarrhoeal and malabsorptive disease, its fruit and bark appearing throughout the recipes of Charaka’s chapters on Atisara and Grahani. (Paraphrase of the classical tradition — not a verbatim verse; classical verse numbering varies by edition.)

Kutaja’s standing rests on a genuine combination of classical authority and real, if still incomplete, pharmacology. Used wisely it can complement conventional care for resistant dysenteric illness or for functional bowel disorders that have not responded fully to standard management. It is not a substitute for diagnosis: “treatment-resistant” sometimes signals the limits of a single approach, but it can equally signal a missed diagnosis, and Kutaja should be added to proper investigation rather than used to delay it.

Consult your Ayurvedic practitioner and a gastroenterologist before using Kutaja, particularly for serious infections, inflammatory bowel disease, or any condition requiring medical diagnosis. Bloody diarrhoea requires prompt medical evaluation to rule out serious causes. Never substitute herbal treatment for medical investigation of acute gastrointestinal symptoms. Consult your healthcare provider before starting any supplement protocol.

References

1. Charaka Samhita — Atisara Chikitsa
2. Sciencedirect (sciencedirect.com)
3. Steroidal alkaloids from Holarrhena antidysenterica (L.) WALL (2007), PubMed
4. Anti-malarial property of steroidal alkaloid conessine isolated from the bark of Holarrhena antidysenterica (2013), PubMed Central
5. A Randomized Single Blind Parallel Group Study Comparing Monoherbal Formulation Containing Holarrhena Antidysenterica Extract with Mesalamine in Chronic Ulcerative Colitis Patients (2016), PubMed Central
6. Easyayurveda (easyayurveda.com)

Boswellia for Inflammatory Bowel Disease: A 2026 Evidence Update

Boswellia serrata, the source of Indian frankincense, has been examined in a small number of human studies involving ulcerative colitis, chronic colitis and Crohn’s disease. The human clinical literature consists mainly of two small colitis reports from 1997 and 2001, one active-Crohn’s comparison from 2001, one placebo-controlled Crohn’s maintenance trial published in 2011, and a 2016 observational registry in ulcerative-colitis remission. A 2024 systematic review of active ulcerative colitis included only the early Gupta trial for Boswellia, while a 2025 review continued to place the plant among candidates requiring further clinical investigation. :contentReference[oaicite:0]{index=0}

Boswellia is therefore best described as an investigational adjunct rather than an established treatment for inflammatory bowel disease (IBD). The older studies provide a reason for continued research, but they do not justify replacing aminosalicylates, corticosteroids, immunosuppressants, biologics, small-molecule medicines or surgery when these are medically indicated. Product identity, extract composition, dose equivalence and objective disease outcomes remain central unresolved issues. :contentReference[oaicite:1]{index=1}

Mechanism Primer: More Complex Than Direct 5-Lipoxygenase Inhibition

Boswellic acids are pentacyclic triterpenes found in Boswellia resin. Acetyl-11-keto-beta-boswellic acid (AKBA) and 11-keto-beta-boswellic acid (KBA) inhibited 5-lipoxygenase and leukotriene formation in cell-free systems and isolated neutrophils. This laboratory finding led to the widely repeated explanation that Boswellia acts primarily by blocking the 5-lipoxygenase pathway. :contentReference[oaicite:2]{index=2}

Physiologically relevant experiments complicate that explanation. In the presence of albumin, inhibition by 11-keto boswellic acids was abolished, and the compounds did not inhibit 5-lipoxygenase product formation in human whole blood. In healthy volunteers, a single 800 mg oral dose of frankincense extract did not suppress plasma leukotriene B4. Pharmacokinetic assessments also found very low plasma concentrations and poor oral absorption of AKBA and KBA relative to the concentrations active in vitro. Direct 5-lipoxygenase inhibition therefore remains a laboratory mechanism, not a demonstrated explanation for clinical benefit in IBD. :contentReference[oaicite:3]{index=3}

Other proposed targets include microsomal prostaglandin E synthase-1 and cathepsin G, particularly for beta-boswellic acid, which reaches higher plasma concentrations than AKBA in pharmacokinetic work. AKBA has also suppressed NF-kappaB signaling in cultured tumor-cell models. These findings broaden the mechanistic hypotheses, but none has been validated as a human IBD biomarker or shown to account for remission in a clinical trial. Boswellia should not be presented as a proven multi-pathway substitute for conventional anti-inflammatory or immune-modifying therapy. :contentReference[oaicite:4]{index=4}

Ayurvedic Identity: Kunduru and Shallaki

The Ayurvedic Pharmacopoeia of India, Part I, Volume IV, monographs the exudate of Boswellia serrata under the name Kunduru and lists Shallaki as its Sanskrit synonym. The monograph identifies the material as an oleo-gum-resin and supplies macroscopic, microscopic, physicochemical and chromatographic standards for identity, purity and strength. This official identity is important because a crude pharmacopoeial exudate is not automatically equivalent to a concentrated commercial extract. :contentReference[oaicite:5]{index=5}

The pharmacopoeial therapeutic-use list does not name ulcerative colitis or Crohn’s disease. Its 1–3 g dose applies to the crude exudate described in that monograph, not to every standardized extract, phospholipid complex or branded supplement. Classical attributes therefore provide an Ayurvedic materia-medica description of Kunduru; they do not by themselves establish a disease-specific indication, a modern extract dose or equivalence with an IBD medicine. :contentReference[oaicite:7]{index=7}

Ulcerative Colitis and Chronic Colitis: What the Human Studies Reported

The best-known report was published by Gupta and colleagues in 1997. Patients with mild-to-moderate active ulcerative colitis received encapsulated powdered Boswellia gum resin or sulfasalazine for six weeks. The original abstract specifies 350 mg three times daily, while the 2024 systematic-review table lists 300 mg three times daily. Remission was reported in 82.4% of the Boswellia group and 75% of the sulfasalazine group, with sigmoidoscopic improvement reported as 75% in each group. :contentReference[oaicite:8]{index=8}

Those percentages do not establish equivalence. The 2024 review rated the study at high risk of bias: allocation was non-randomized, blinding was absent, the sample was small and the reporting of participant numbers and outcomes was inconsistent. Mild gastrointestinal complaints included retrosternal burning, nausea, abdominal fullness, epigastric pain and anorexia. The trial is a historical signal that requires replication rather than a basis for claiming that Boswellia matches sulfasalazine or mesalazine. :contentReference[oaicite:9]{index=9}

A second small study published in 2001 enrolled 30 people described as having chronic colitis. Twenty received Boswellia gum resin at 900 mg daily and ten received sulfasalazine at 3 g daily for six weeks. Fourteen of 20 Boswellia recipients and four of 10 sulfasalazine recipients were reported to enter remission; overall improvement was reported in 90% and 60%, respectively. The small, uneven groups, brief treatment period and older diagnostic description limit direct application to contemporary ulcerative-colitis care. :contentReference[oaicite:10]{index=10}

The 2016 Remission-Phase Registry

A 2016 open-label observational registry followed 43 people with minimally symptomatic ulcerative colitis in remission. Participants chose either a daily lecithin-based Boswellia product, Casperome, or no supplementation for four weeks; 22 entered the supplement group and 21 the comparison group. The publication reported improvements in symptoms and fecal calprotectin among supplemented participants. Because treatment was self-selected, there was no randomization, placebo or blinding, and the study evaluated a short remission-phase interval rather than induction of remission in active disease. :contentReference[oaicite:11]{index=11}

The registry supports further investigation of delivery systems, but it does not establish that a phospholipid formulation is clinically superior to a conventional extract, that lower doses are therapeutically equivalent, or that the product maintains remission over months or years. Its findings should not be extended to active ulcerative colitis or Crohn’s disease without controlled trials. :contentReference[oaicite:12]{index=12}

Crohn’s Disease: Active Treatment and Remission Maintenance

In 2001, a randomized, double-blind, active-comparator study assigned 102 people with active Crohn’s disease to the Boswellia extract H15 or mesalazine. The published per-protocol analysis included 83 participants. Crohn’s Disease Activity Index scores fell in both groups, and the study’s analysis met its prespecified non-inferiority criterion for H15 over eight weeks. This was an active-comparator study using a clinical activity index; it was not a placebo-controlled demonstration of mucosal healing, durable steroid-free remission or prevention of complications. :contentReference[oaicite:13]{index=13}

The more rigorous maintenance test was less favorable. A randomized, placebo-controlled, double-blind trial evaluated Boswellia extract for 52 weeks in people whose Crohn’s disease was in remission. Among 82 participants summarized in the evidence record, 60% in the Boswellia group and 55% in the placebo group remained in remission. The difference was not significant, and adverse-event rates and laboratory findings were similar. The trial therefore did not establish efficacy for maintaining Crohn’s remission. :contentReference[oaicite:14]{index=14}

Formulation and Dose: Why Milligrams Are Not Interchangeable

The human studies used materially different products: powdered gum resin, H15, another Boswellia extract used for Crohn’s maintenance and a lecithin-based product. A label may specify total Boswellia extract, total boswellic acids, AKBA, KBA or another proprietary standard, and these quantities do not establish clinical equivalence. The Ayurvedic Pharmacopoeia’s 1–3 g dose for Kunduru exudate cannot be converted directly into a dose of a concentrated extract. :contentReference[oaicite:16]{index=16}

AKBA and KBA have limited oral absorption in conventional pharmacokinetic work, which is one reason enhanced-delivery products are being developed. Improved plasma exposure, however, is not the same as clinical efficacy in IBD. The available ulcerative-colitis registry does not provide a randomized comparison between lecithin-based and conventional preparations, and the Crohn’s trials do not establish an AKBA threshold that predicts response. A universal recommendation such as “at least 10% AKBA” is not supported by the human IBD trials. :contentReference[oaicite:17]{index=17}

A universally accepted Boswellia dose for active or maintenance IBD has not been established. Historical trial doses describe the tested products only. NCCIH notes apparent oral safety for some extracts at up to 1,000 mg daily for as long as six months and at 2,400 mg daily for up to one month, but these exposure statements are not efficacy recommendations for ulcerative colitis or Crohn’s disease. :contentReference[oaicite:18]{index=18}

Safety, Quality and Drug Interactions

Across the small studies and broader supplement literature, Boswellia has generally been tolerated, with gastrointestinal complaints such as nausea, abdominal discomfort, heartburn, diarrhea or constipation among the reported effects. LiverTox has not linked Boswellia convincingly to clinically apparent liver injury, although detailed prospective safety data are limited. “Natural” and “well tolerated” do not guarantee that every product is pure, correctly labeled or suitable for a person with active IBD. :contentReference[oaicite:19]{index=19}

Memorial Sloan Kettering advises caution with anticoagulant or antiplatelet medicines because Boswellia extracts can inhibit platelet aggregation and may increase bleeding risk; the clinical importance remains uncertain. Boswellia extracts and keto-boswellic acids have also affected P-glycoprotein, OATP1B3 and MRP2 in vitro, but clinically established dosing adjustments have not been defined. Specific interactions with azathioprine, 6-mercaptopurine, ciclosporin, tacrolimus, anti-TNF biologics or CYP3A4 substrates have not been demonstrated in human IBD trials. :contentReference[oaicite:20]{index=20}

Quality control matters because resin powders, standardized extracts and multi-ingredient products may differ substantially. A product considered for supervised use should identify the botanical species and plant material, state the extract amount and standardization method, provide batch testing for identity and contaminants, and disclose all additional ingredients. These quality features reduce uncertainty but do not convert a supplement into an approved IBD treatment. :contentReference[oaicite:21]{index=21}

Safety disclaimer: Ulcerative colitis and Crohn’s disease require diagnosis, monitoring and treatment by a gastroenterologist. Boswellia should not replace prescribed medicine, and no corticosteroid, immunosuppressant, biologic, small-molecule drug or aminosalicylate should be stopped or reduced without the treating clinician. Discuss any Boswellia product with the gastroenterologist and a qualified Ayurvedic practitioner, especially during pregnancy or breastfeeding, before surgery, or when using anticoagulant, antiplatelet or other prescription medicines. :contentReference[oaicite:22]{index=22}

Where the Evidence Gaps Remain

The principal gap is a reproducible clinical program using a chemically characterized preparation. Future trials need verified batch consistency, adequate allocation concealment and blinding, sufficient sample size, intention-to-treat analysis and prespecified safety monitoring. Active ulcerative-colitis studies should distinguish induction from maintenance and should measure symptoms together with endoscopic and, where appropriate, histologic inflammation. Crohn’s studies should report disease location, prior biologic exposure, steroid-free remission and objective inflammatory outcomes rather than relying on symptom indices alone. :contentReference[oaicite:23]{index=23}

Pharmacokinetic work should accompany efficacy trials so that exposure to individual boswellic acids can be related to outcomes without assuming AKBA is the sole active constituent. Head-to-head formulation studies are needed before claiming that phytosomes, micelles, self-emulsifying systems or other delivery technologies permit lower therapeutic doses. Combination studies with mesalazine, immunomodulators or biologics would also require interaction monitoring and enough power to separate additive benefit from background therapy. :contentReference[oaicite:24]{index=24}

Pediatric use, pregnancy, long-term relapse prevention and use after intestinal surgery remain insufficiently characterized. Microbiome findings from laboratory or animal work should not be converted into human treatment claims until clinical studies connect defined microbial changes with objective IBD outcomes. The same standard applies to combinations with curcumin, probiotics or other Ayurvedic herbs: theoretical complementarity is not a substitute for controlled safety and efficacy data. :contentReference[oaicite:25]{index=25}

Clinical Takeaways for 2026

As of 2026, Boswellia is not established as a first-line therapy for ulcerative colitis or Crohn’s disease. Small historical colitis comparisons and one short observational remission registry reported favorable findings, while the placebo-controlled Crohn’s maintenance trial did not demonstrate superiority. The active-Crohn’s H15 study met its own non-inferiority criterion against mesalazine but did not provide the objective, durable outcomes expected of a modern confirmatory program. :contentReference[oaicite:26]{index=26}

For patients and clinicians, the practical position is cautious and specific: Boswellia may be discussed as a supervised adjunct when the product is clearly identified and the treatment plan includes continued medical monitoring. It should not be used to delay effective therapy or to infer healing from symptom improvement alone. For researchers, the priority is a well-powered, independently conducted trial using a characterized preparation and objective inflammatory endpoints. Until such data are available, Boswellia remains a plausible but unproven IBD intervention. :contentReference[oaicite:27]{index=27}

References

1. Ayurvedic Pharmacopoeia of India
2. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance (2009), PubMed
3. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data (2011), PubMed
4. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression (2006), PubMed
5. Effects of Boswellia serrata gum resin in patients with ulcerative colitis (1997), PubMed
6. Mdpi (mdpi.com)
7. Effects of gum resin of Boswellia serrata in patients with chronic colitis (2001), PubMed
8. [Therapy of active Crohn disease with Boswellia serrata extract H 15] (2001), PubMed
9. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy (2011), PubMed
10. Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extract (2016), PubMed
11. NCBI
12. NCCIH
13. Mskcc (mskcc.org)
14. NIDDK
15. NIDDK
16. Emerging Natural Therapies for the Treatment of Inflammatory Bowel Disease (2025), PubMed

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

A small comparative study published in 1997 reported similar remission proportions among patients with ulcerative colitis treated with Boswellia serrata gum resin and those treated with sulfasalazine. That finding encouraged interest in Boswellia, but its small sample, limited methodological detail, and the later failure of Boswellia to maintain remission in a placebo-controlled Crohn’s disease trial prevent it from being treated as an established alternative to conventional care. A 2025 scoping review in Cureus assembled a broader collection of clinical and preclinical research on Ayurvedic herbs and formulations for inflammatory bowel disease (IBD). The review identified promising signals, especially for curcumin as an adjunct in ulcerative colitis, while also revealing substantial gaps in study quality, standardization, and long-term safety data.

What the Scoping Review Covered

The review was authored by Vakiti and colleagues and published on May 19, 2025. It searched Embase, PubMed, and Cochrane Central for literature published from January 2003 through September 2023 and analyzed 25 full-text articles. IBD includes ulcerative colitis and Crohn’s disease, but the Ayurvedic evidence identified by the reviewers was concentrated more heavily on ulcerative colitis and experimental colitis models.

The included literature was not a uniform collection of randomized clinical trials. It combined human studies with animal experiments and evaluated single-herb extracts, isolated plant constituents, multicomponent formulations, and procedure-based Ayurvedic regimens. Consequently, its findings cannot be combined into one reliable estimate of treatment effect.

Outcomes described across individual papers included:

• Changes in stool frequency, urgency, mucus, rectal bleeding, abdominal discomfort, and general well-being
• Clinical activity, relapse, endoscopic, or sigmoidoscopic measurements in some human studies
• Colon length, colon weight, tissue injury, ulceration, and histological scores in animal models
• Experimental measurements such as myeloperoxidase activity, oxidative-stress markers, cytokines, and prostaglandin E2

These outcomes are not interchangeable. A reduction in a laboratory inflammatory marker in rats may help identify a biological effect, but it does not establish remission, mucosal healing, steroid-free control, or long-term safety in people with IBD. The scoping review is therefore best understood as a map of the available literature rather than proof that the interventions are clinically equivalent to approved medicines.

The Better-Documented Herbs and Formulations

Several plants appeared in human or preclinical studies reviewed in this field. The strongest interpretations come from examining each intervention separately and distinguishing adjunctive human evidence from exploratory animal findings.

Boswellia serrata (Kunduru or Shallaki)

The Ayurvedic Pharmacopoeia of India identifies Kunduru as the oleo-gum resin of Boswellia serrata and lists Shallaki among its Sanskrit synonyms. Boswellic acids and other resin constituents have been investigated for effects on leukotriene-related and additional inflammatory pathways, although the activity of a constituent in laboratory experiments does not establish the clinical effectiveness of a commercial Boswellia supplement.

In the 1997 comparative study, 42 patients with grade II or III ulcerative colitis received either Boswellia gum resin at 350 mg three times daily or sulfasalazine at 1 g three times daily for six weeks. The publication reported remission in 82% of Boswellia-treated patients and 75% of sulfasalazine-treated patients. These percentages should be interpreted cautiously because the study was small, the treatment groups were unbalanced, and the report does not provide the methodological safeguards expected of a modern blinded, adequately powered non-inferiority trial.

A separate 2001 study enrolled 30 patients with chronic colitis and also reported favorable outcomes with Boswellia, but it was again a small comparison. Importantly, a later randomized, double-blind, placebo-controlled trial found that a Boswellia extract was well tolerated but did not outperform placebo in maintaining remission in Crohn’s disease. The total evidence therefore supports further investigation rather than a conclusion that Boswellia can replace established IBD therapy.

Turmeric and Curcumin (Haridra)

The Ayurvedic Pharmacopoeia identifies Haridra as the rhizome of Curcuma longa. Curcumin is one group of constituents obtained from turmeric, but purified curcumin products, enhanced-bioavailability preparations, whole turmeric powder, and classical Haridra formulations are not pharmacologically identical and should not be treated as interchangeable interventions.

The most frequently cited clinical study was a 2006 randomized, multicenter, double-blind, placebo-controlled maintenance trial involving 89 people with quiescent ulcerative colitis. Participants continued sulfasalazine or mesalamine and received either curcumin at 2 g per day or placebo for six months. In the per-protocol analysis, 2 of 43 participants receiving curcumin relapsed, compared with 8 of 39 receiving placebo, corresponding to 4.65% versus 20.51%. Clinical and endoscopic indices also favored the curcumin group during treatment.

This trial evaluated curcumin as an adjunct, not as a replacement for maintenance medication. Results have also varied between curcumin studies. A later randomized trial using a comparatively low oral dose of 450 mg per day did not induce remission in mild-to-moderate active ulcerative colitis. Dose, formulation, absorption, disease activity, treatment duration, and accompanying medication may all influence the result. Curcumin consequently has a more credible adjunctive evidence base than many herbs in the review, but the optimal preparation and regimen remain unsettled.

Amorphophallus paeoniifolius

Amorphophallus paeoniifolius, commonly called elephant-foot yam, was studied in chemically induced ulcerative colitis in rats. Methanolic and aqueous tuber extracts improved several experimental measures, including inflammatory and oxidative-damage findings in colonic tissue. Prednisolone was included as a reference treatment, and some measurements with the plant extracts compared favorably in that model.

These findings do not demonstrate superiority to corticosteroids in patients. Animal colitis is deliberately induced under controlled conditions and does not reproduce the full immunological, genetic, microbial, and relapsing course of human ulcerative colitis. The study provides a basis for identifying active constituents and designing safety studies, not for prescribing the tuber extract in place of steroid treatment during an IBD flare.

Kutaja (Holarrhena antidysenterica)

The Ayurvedic Pharmacopoeia identifies Kutaja stem bark as Holarrhena antidysenterica. Kutaja has a longstanding place in Ayurvedic formulations for diarrheal presentations, but a traditional indication does not by itself establish efficacy for ulcerative colitis, which is a distinct immune-mediated disease requiring biomedical diagnosis and monitoring.

A 2016 randomized, single-blind study enrolled 30 patients with chronic ulcerative colitis. Ten participants each received mesalamine, a monoherbal Holarrhena antidysenterica tablet, or both treatments. All three groups improved, and the authors reported greater changes in several symptom scores in the herb-only group, as well as fewer reported relapses after treatment withdrawal in the groups receiving the herb. However, groups of only 10 people are highly vulnerable to baseline imbalance, chance findings, and unstable relapse estimates. The trial is a useful pilot study but is not large enough to establish equivalence or superiority to mesalamine.

Bilva (Aegle marmelos)

Bilva is identified in the Ayurvedic Pharmacopoeia as Aegle marmelos, with separate standards for plant parts such as fruit pulp and stem bark. Extracts of dried fruit pulp have been evaluated in rat models of chemically induced colitis. These experiments reported improvements in colonic damage, tissue findings, and selected inflammatory or oxidative-stress measurements.

The reviewed evidence does not substantiate the earlier claim that Bilva fruit pulp improved stool frequency in human ulcerative colitis trials. The relevant studies are predominantly preclinical. They may support investigation of the fruit’s constituents and traditional gastrointestinal applications, but they cannot define an effective human dose or demonstrate clinical remission.

Pomegranate (Punica granatum)

Pomegranate, Punica granatum, contains ellagitannins that can be converted by intestinal microorganisms into metabolites called urolithins. Pomegranate extracts, peel, rind, and isolated constituents have been examined in laboratory and animal models of intestinal inflammation. One animal study also evaluated Aegle marmelos and Punica granatum in experimentally induced gastrointestinal barrier dysfunction.

The preparation matters: juice, fruit, rind extract, peel extract, purified punicalagin, and ellagic acid have different compositions and cannot be assigned one common dose or effect. Human evidence sufficient to recommend pomegranate preparations as a treatment for active IBD has not been established by these preclinical findings.

A Closer Look at the 43-Patient Ayurvedic Study

The frequently cited study of 43 patients was published in AYU in 2010, not 2011. It did not test a Basti containing Picrorhiza kurroa and Boswellia. Participants received Udumbara kvatha Basti together with oral Kutaj ghan vati, Udumbara kvatha, and a combination containing Musta, Nagakesara, Lodhra, and Mukta panchamrut rasa for one month.

The authors interpreted ulcerative-colitis symptoms through an Ayurvedic framework involving Atisara and Raktatisara and cited the description of Piccha Basti in the Charaka Samhita. Such comparison can guide Ayurvedic clinical reasoning, but Raktatisara is not a biomedical synonym for ulcerative colitis. UC must still be diagnosed and assessed through appropriate gastroenterological evaluation, including endoscopic and laboratory findings when indicated.

The study reported substantial reductions in bowel frequency, rectal bleeding, abdominal pain, stool red blood cells, and use of prednisolone or sulfasalazine, together with an increase in hemoglobin. Because every participant received several interventions and there was no randomized control or placebo group, the contribution of the Basti, each oral medicine, concurrent conventional treatment, natural fluctuation, and observer expectation cannot be separated. The one-month duration also provides little information about sustained remission or delayed adverse effects.

Study Comparison: Selected Human and Animal Evidence

The principal studies differ greatly in design, population, treatment composition, and reliability. Placing them side by side shows why positive results cannot be treated as one unified clinical conclusion.

How to Interpret the Inflammatory-Pathway Findings

The review described changes in cytokines, prostaglandins, oxidative-stress markers, myeloperoxidase activity, tissue injury, and related experimental outcomes. Curcumin, Boswellia constituents, pomegranate polyphenols, and other plant compounds have each been investigated for effects on signaling pathways associated with inflammation.

Pathway overlap should not be confused with therapeutic equivalence. A plant extract that changes TNF-alpha expression in cells or animals is not thereby equivalent to an anti-TNF monoclonal antibody. Biologic medicines have defined molecular targets, standardized manufacturing, pharmacokinetic data, dose-ranging studies, controlled clinical trials, and ongoing safety surveillance. Herbal extracts may contain numerous constituents whose concentration, absorption, metabolism, and combined effects vary between products.

Multi-component Ayurvedic treatment may act through several physiological processes at once, but it also makes causal interpretation more difficult. When diet, several oral medicines, Basti, and conventional drugs are used together, a study must be designed specifically to determine whether the complete program adds benefit and whether any individual component is necessary.

What the Evidence Does and Does Not Establish

The 2025 review documents a real body of Ayurvedic and plant-based IBD research, but the evidence remains heterogeneous and cannot support a blanket statement that Ayurvedic herbs match or outperform conventional medicines.

• Many studies were small. Several human comparisons enrolled only 30 to 43 people, and some divided them into groups of 10 or fewer.
• Preclinical and clinical evidence were combined. Tissue changes in animal models are valuable for hypothesis generation but cannot be counted as human remission outcomes.
• Interventions differed substantially. Studies tested whole resins, extracts, purified constituents, tablets, polyherbal combinations, and procedural regimens.
• Outcome measures were inconsistent. Symptoms, laboratory values, endoscopic assessments, histology, cytokines, and animal disease scores answer different questions.
• Blinding and control groups were often absent. This increases the influence of spontaneous improvement, concurrent treatment, selection effects, and observer expectations.
• Long-term information was limited. IBD is relapsing and chronic, so brief improvement does not establish durable remission, mucosal healing, or long-term safety.

A scoping review is designed principally to describe the range and characteristics of published literature. It does not automatically provide a pooled effect estimate, establish comparative effectiveness, or correct weaknesses in the studies it includes.

Safety and Clinical Integration

Ayurvedic herbs and supplements should not be used to stop or reduce prescribed IBD medication without the treating gastroenterologist’s supervision. Guideline-based treatment may include 5-aminosalicylates such as mesalamine for mild-to-moderate ulcerative colitis and corticosteroids, immunomodulators, biologics, or targeted small-molecule medicines for appropriate moderate-to-severe disease. Treatment choice depends on diagnosis, disease location, severity, previous response, complications, and individual risk.

Turmeric or curcumin products may cause digestive adverse effects, and formulations designed to increase absorption may have different safety characteristics from ordinary turmeric preparations. Boswellia appears reasonably well tolerated in short clinical studies, but evidence about prolonged use and use alongside complex IBD regimens is more limited. Herbal products and medicines can also interact, and the composition of supplements may vary.

Patients considering adjunctive Ayurvedic care should consult both a gastroenterologist and a qualified Ayurvedic practitioner who is willing to coordinate treatment. The complete product name, botanical ingredients, extract ratio, dose, manufacturer, and any metallic or mineral ingredients should be disclosed. Persistent bleeding, dehydration, fever, severe abdominal pain, rapid deterioration, or suspected complications require prompt conventional medical assessment rather than self-treatment.

Where the Research Needs to Go

The most useful next step is not simply to publish more positive case reports. Future studies need designs capable of distinguishing a genuine, clinically important treatment effect from natural variation and bias.

1. Conduct preregistered, adequately powered, multicenter randomized trials using clearly defined background therapy and control groups.
2. Standardize botanical identity, plant part, extraction method, constituent profile, dose, and contaminant testing, with reference to recognized pharmacopoeial standards where applicable.
3. Use validated clinical, biochemical, endoscopic, and histological endpoints rather than relying only on unvalidated symptom scores.
4. Separate induction of remission from maintenance of remission and follow participants long enough to document relapse, steroid exposure, hospitalization, surgery, and adverse events.
5. Evaluate Ayurvedic interventions first as carefully monitored adjuncts before making comparisons with established medicines as replacements.
6. Report negative and neutral results, including treatment withdrawals and laboratory abnormalities, as completely as favorable findings.

The Bottom Line

The 2025 scoping review identified 25 articles describing Ayurvedic herbs, plant-derived compounds, and multicomponent treatments relevant to IBD. The most persuasive human signal in the reviewed field is the 2006 trial of curcumin added to sulfasalazine or mesalamine for maintenance of ulcerative-colitis remission. Small Boswellia and Kutaja studies are encouraging but methodologically insufficient, while findings for Amorphophallus paeoniifolius, Bilva, and pomegranate remain largely preclinical.

The evidence supports cautious, rigorous investigation rather than claims of proven equivalence to mesalamine, corticosteroids, or biologic therapy. Properly standardized Ayurvedic interventions may eventually earn a defined complementary role, but current evidence does not justify replacing prescribed IBD treatment. Any integration should be individualized, quality-controlled, and coordinated with qualified Ayurvedic and gastroenterology professionals.

References

1. The Efficacy of Ayurvedic Herbs in the Prevention and Treatment of Inflammatory Bowel Disease: A Scoping Review (2025), PubMed
2. The Efficacy of Ayurvedic Herbs in the Prevention and Treatment of Inflammatory Bowel Disease: A Scoping Review (2025), PubMed Central
3. Europepmc (europepmc.org)
4. NCBI
5. Ayurvedic Pharmacopoeia of India
6. Effects of Boswellia serrata gum resin in patients with ulcerative colitis (1997), PubMed
7. Effects of gum resin of Boswellia serrata in patients with chronic colitis (2001), PubMed
8. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy (2011), PubMed
9. Ayurvedic Pharmacopoeia of India
10. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial (2006), PubMed
11. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial (2017), PubMed
12. Beneficial effect of Amorphophallus paeoniifolius tuber on experimental ulcerative colitis in rats (2017), PubMed
13. A Randomized Single Blind Parallel Group Study Comparing Monoherbal Formulation Containing Holarrhena Antidysenterica Extract with Mesalamine in Chronic Ulcerative Colitis Patients (2016), PubMed
14. Effects of Ayurvedic treatment on forty-three patients of ulcerative colitis (2010), PubMed
15. Effects of Ayurvedic treatment on forty-three patients of ulcerative colitis (2010), PubMed Central
16. Pdfs (pdfs.semanticscholar.org)
17. Protective effects of Aegle marmelos fruit pulp on 2,4,6-trinitrobenzene sulfonic acid-induced experimental colitis (2014), PubMed Central
18. Ijbcp (ijbcp.com)
19. Frontiersin (frontiersin.org)
20. Patient (patient.gastro.org)
21. Gastro (gastro.org)
22. NCCIH
23. NCCIH
24. NCCIH
25. Crohnscolitisfoundation (crohnscolitisfoundation.org)
26. Ayurvedic Pharmacopoeia of India

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.